Beijing Gene+ Technology closed a $28 million B round led by Co-Stone to advance its oncology gene testing services. The company’s $30 million A round, completed in 2016, was led by BGI Group, China’s largest genetics sequencing company, which also contributed to the B round along with previous investor Green Pine Capital Partners and Volcanics Venture. Founded in 2015 Gene+ offers tests that assess an individual’s genetic risk for developing cancer as well as early detection services and precision medicine guidance.
Source: China Biotoday
